[Skip to Content]
[Skip to Content Landing]
Views 539
Citations 0
Observation
May 20, 2020

Bullous and Exanthematous Lesions Associated With Chimeric Antigen Receptor T-Cell Therapy in a Patient With Diffuse Large B-Cell Lymphoma

Author Affiliations
  • 1Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
  • 2Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, Zhejiang, China
  • 3Institute of Hematology, Zhejiang University, Hangzhou, Zhejiang, China
  • 4Department of Dermatology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
  • 5Department of Hematology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
  • 6Shanghai YaKe Biotechnology Ltd, Shanghai, China
JAMA Dermatol. Published online May 20, 2020. doi:10.1001/jamadermatol.2020.0636

Chimeric antigen receptor T-cell (CAR-T) therapy has revolutionized treatment modalities for patients with relapsed/refractory hematologic cancers.1 As CAR-T therapy becomes more widely applied, toxic effects unique to CAR-T treatment are being identified that may potentially affect any organ or system.2 We report a case of a cutaneous toxic reaction after CAR-T therapy.

Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    ×